Granulocyte transfusion: current status.
Infection associated with therapy-related neutropenia continues to be a major cause of morbidity and mortality. Renewed interest in granulocyte transfusion therapy as treatment for this condition has been generated by the observation that large doses of granulocytes can be obtained from donors who have been stimulated with granulocyte colony-stimulating factor (G-CSF). Granulocytes collected from these donors have been shown to effectively raise the patient's neutrophil count and appear to function normally as judged both by in vitro and in vivo measures. The evidence for clinical efficacy is limited to that of case reports and small series, and the results are not uniform. Randomized controlled clinical trials are needed to determine whether this therapy is useful in either clearing infections or prolonging survival.
Price
Thomas H
TH
Puget Sound Blood Center and Department of Medicine, University of Washington, Seattle, WA 98104, USA. thprice@psbc.org
D016022:Case-Control Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D017708:Leukocyte Transfusion / Q000009:adverse effects*; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor